Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 3206-3214 | ISSN:2251-6727

Adamantane Derivatives in the 21st Century: Emerging Therapeutic Frontiers and Future Research Directions

Ashwin Akbari[1,2] Jigar Y. Soni[*2]

1Directorate of Forensic Science, Document Division, Gandhinagar-382007, India,

2Dr. Jigar Y. Soni, Madhav University, Department of Chemistry, Department of Basic and Applied Science, Pindwara(Shirohi)-307022, India

(Received: 27 September 2025 Revised: 05 October 2025 Accepted: 14 October 2025)

KEYWORDS

Adamantane, anti viral,anti microbial, anti parasitic, Anti cancer

ABSTRACT:
Adamantane, first synthesized in 1933 by Prelog and Seiwerth, represents the simplest member of the diamondoid hydrocarbon family, consisting of a highly symmetric tricyclic aliphatic framework (Prelog and Seiwerth, 1933). It gained prominence in the 1960s when its derivatives were developed as antiviral agents, ushering in a new era of drug discovery (Von Itzstein, 2007). Since then, adamantane chemistry has been extensively explored for its versatile functionalization, leading to derivatives with applications across virology, neurology, oncology, and materials science (Stankiewicz et al., 2019).

1. Introduction

Overview of Adamantane Chemistry and Its Discovery

Adamantane, first synthesized in 1933 by Prelog and Seiwerth, represents the simplest member of the diamondoid hydrocarbon family, consisting of a highly symmetric tricyclic aliphatic framework (Prelog and Seiwerth, 1933). It gained prominence in the 1960s when its derivatives were developed as antiviral agents, ushering in a new era of drug discovery (Von Itzstein, 2007). Since then, adamantane chemistry has been extensively explored for its versatile functionalization, leading to derivatives with applications across virology, neurology, oncology, and materials science (Stankiewicz et al., 2019).

Structural Uniqueness: Rigid Diamondoid Framework, Lipophilicity, and Ability to Cross Biological Membranes

The adamantane scaffold is characterized by a rigid, three-dimensional diamondoid structure, conferring exceptional metabolic stability and resistance to enzymatic degradation (Liu et al., 2017). Its lipophilic cage structure enhances penetration across lipid membranes, making it a privileged motif in medicinal chemistry (Chaudhuri and Ahmed, 2019). Moreover, the steric bulk and hydrophobicity of adamantane allow selective interactions with hydrophobic pockets of viral proteins, ion channels, and receptors, which has been exploited in antiviral and neuroprotective drugs (Aznar and Sabater, 2020).

Historical Therapeutic Applications (Amantadine, Rimantadine, Memantine)

The first major therapeutic success of adamantane derivatives was **amantadine**, approved in the 1960s for the prevention and treatment of influenza A infections through inhibition of the M2 proton channel (Davies et al., 1964). Shortly thereafter, **rimantadine**, a structural analog, was introduced with enhanced antiviral potency and better tolerability (Hay et al., 1985). Another milestone was **memantine**, an NMDA receptor antagonist that remains a cornerstone in the treatment of moderate to severe Alzheimer's disease due to its neuroprotective effects and favorable safety profile (Lipton, 2004; Parsons et al., 2007). These drugs established adamantane as a pharmacophoric scaffold of great clinical relevance.

Rationale for Renewed Interest in 21st Century Drug Discovery

Despite early therapeutic breakthroughs, widespread drug resistance and limitations in clinical efficacy led to a decline in adamantane use in the late 20th century (Bright et al., 2006). However, the 21st century has witnessed a resurgence of interest driven by several factors: the emergence of multidrug-resistant pathogens, advances in computational drug design, and the recognition of adamantane's potential in multitargeted and hybrid therapeutics (Kumar et al., 2020). Recent studies highlight adamantane conjugates as promising candidates in oncology, neurodegeneration, and novel viral threats such as coronaviruses (Mehta et al., 2021). This renewed focus underscores the adaptability of the scaffold for next-generation drug development.

Scope and Objectives of the Review

This review aims to provide a comprehensive synthesis of the **recent advances in adamantane derivatives in the 21st century**, with a focus on their synthetic modifications, pharmacological applications, and translational prospects. By evaluating current therapeutic frontiers—including antiviral, anticancer, neuroprotective, and nanomedicine applications—this work seeks to outline not only the progress achieved but also the **future research directions** necessary for optimizing adamantane scaffolds in modern drug discovery.

2. Synthetic Advances in Adamantane Chemistry

Recent Synthetic Strategies: Functionalization, C–H Activation, and Green Chemistry Methods

The unique cage-like framework of adamantane poses challenges in direct functionalization due to its chemical inertness. However, recent advances in **C–H activation techniques** have enabled site-selective modifications, particularly at bridgehead and tertiary carbons (Chen et al., 2019). Transition-metal catalysis, including palladium and rhodium-mediated activation, has been exploited to introduce functional groups such as halogens, amines, and hydroxyl moieties (Zhang et al., 2018). Beyond classical halogenation and nitration, **photocatalysis and radical-mediated reactions** have opened eco-friendly pathways to generate functionalized derivatives with higher atom economy (Li et al., 2020). Green chemistry approaches, such as solvent-free conditions and the use of ionic liquids, are increasingly applied to reduce environmental impact in adamantane synthesis (Kamal et al., 2021).

Design of Hybrid Molecules with Adamantane Moieties

In medicinal chemistry, hybridization strategies that incorporate the adamantane scaffold with pharmacophores from other bioactive compounds have yielded molecules with **dual or multitargeted therapeutic activity** (Mandal et al., 2019). Examples include adamantane-linked triazoles with potent antifungal properties, adamantane-chalcone hybrids with anticancer potential, and adamantane-quinoline conjugates showing enhanced antimalarial activity (Gomha et al., 2020). The rigid hydrophobic framework enhances binding affinity, while hybridization often improves solubility, pharmacokinetics, and target selectivity (Singh et al., 2021). These hybrids represent a versatile avenue for addressing complex diseases such as cancer and multidrug-resistant infections.

Nanotechnology and Adamantane Conjugates (Drug Delivery, Targeting)

Adamantane has gained prominence in **nanomedicine** owing to its ability to act as a lipophilic anchor for supramolecular assemblies. Its integration into **dendrimers, cyclodextrins, and polymeric nanoparticles** has facilitated drug encapsulation, targeted delivery, and controlled release (Fetih et al., 2017). Notably, adamantane-modified cyclodextrins have been used to enhance water solubility and bioavailability of poorly soluble drugs (Loftsson and Brewster, 2012). Furthermore, adamantane-based conjugates in liposomal and micellar systems have shown promise for crossing the blood–brain barrier, thereby expanding their role in central nervous system drug delivery (Kumar et al., 2022). In nanotechnology-enabled therapies, adamantane derivatives function both as active pharmacophores and as carriers, reflecting their dual utility.

Emerging Computational and AI-Driven Approaches in Derivative Design

The application of **computational chemistry and artificial intelligence (AI)** has revolutionized the design of novel adamantane derivatives. Molecular docking, molecular dynamics (MD) simulations, and quantitative structure–activity relationship (QSAR) models are being used to predict binding interactions with viral proteins, receptors, and enzymes (Zhou et al., 2021). Machine

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 3206-3214 | ISSN:2251-6727

learning algorithms trained on experimental datasets enable **virtual screening of adamantane libraries**, accelerating the identification of lead compounds (Zhang and Xu, 2022). Recent studies have applied AI-guided generative models to propose adamantane-inspired scaffolds with enhanced drug-likeness and ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles (Wang et al., 2023). Such computational frameworks complement synthetic chemistry, reducing costs and timelines associated with drug development.

3. Pharmacological Landscape of Adamantane Derivatives

3.1 Antiviral Activity

Adamantane derivatives first gained global attention as **influenza A inhibitors**, with amantadine and rimantadine blocking the viral M2 proton channel (Davies et al., 1964; Hay et al., 1985). However, rapid emergence of resistance limited their long-term use (Bright et al., 2006). Recent research has expanded to novel viral targets including **HIV**, where adamantane-based protease inhibitors have shown inhibitory activity (Mehta et al., 2020), and **Zika virus**, where adamantane conjugates demonstrated RNA replication interference (Haviernik et al., 2018). The COVID-19 pandemic renewed interest in adamantane scaffolds, with studies reporting potential binding to SARS-CoV-2 main protease and spike protein interfaces (Wu et al., 2021). To overcome resistance, structural modifications such as **fluorination, hybridization with heterocycles, and C–H activated derivatives** have yielded more potent analogs with broader antiviral profiles (Kumar et al., 2020).

3.2 Neuroprotective and CNS Applications

The success of **memantine**, an NMDA receptor antagonist, highlighted the role of adamantane in treating **Alzheimer's disease** by reducing excitotoxicity and improving cognitive function (Lipton, 2004; Parsons et al., 2007). Beyond Alzheimer's, adamantane derivatives are being investigated in **Parkinson's disease**, where amantadine provides symptomatic relief by modulating dopaminergic neurotransmission (Schapira and Olanow, 2004). Novel analogs are designed as **dual-action molecules**, combining NMDA receptor antagonism with anti-inflammatory properties to address the multifactorial pathophysiology of neurodegeneration (Matsunaga et al., 2015). Preclinical studies indicate their potential in traumatic brain injury, epilepsy, and Huntington's disease (Chen et al., 2019). Thus, the adamantane scaffold continues to serve as a **privileged structure in neurotherapeutics**.

3.3 Anticancer Potential

Adamantane derivatives exhibit diverse **anticancer mechanisms**, including inhibition of tyrosine kinases, induction of apoptosis, and DNA intercalation (Sharma et al., 2020). For example, adamantane-based chalcones and triazoles have shown cytotoxic effects against breast (MCF-7), lung (A549), and colon (HT-29) cancer cell lines (Mehta et al., 2020). Hybrid formulations, such as adamantane-conjugated platinum complexes, demonstrate enhanced cytotoxicity and reduced systemic toxicity compared to traditional chemotherapeutics (Singh et al., 2021). Prodrug strategies have also been employed, improving solubility and tumor-specific release (Kumar et al., 2019). Preclinical evaluations confirm strong anticancer potential, while early-stage clinical investigations are exploring adamantane conjugates as adjuvant therapies (Rana et al., 2022).

3.4 Antimicrobial and Antiparasitic Agents

The rise of multidrug-resistant pathogens has spurred the development of **adamantane-based antimicrobials**. Derivatives functionalized with hydrazones, Schiff bases, and triazoles have shown strong activity against resistant *Staphylococcus aureus* and *Escherichia coli* strains (Liu et al., 2017). Adamantane-antibiotic hybrids, particularly with quinolones and macrolides, enhance antibacterial potency and overcome resistance barriers (Chaudhuri and Ahmed, 2019). In parasitology, adamantane-chloroquine hybrids display antimalarial efficacy by synergistically targeting parasite heme metabolism (Gomha et al., 2020). Antifungal hybrids incorporating adamantane moieties with azoles have also demonstrated activity against resistant *Candida* strains (Mandal et al., 2019). These findings highlight adamantane's versatility in **antimicrobial and antiparasitic drug discovery**.

3.5 Other Therapeutic Applications

Beyond their established roles, adamantane derivatives have found applications in **cardiovascular and metabolic disorders**. Adamantane-based inhibitors of lipid metabolism have shown promise in controlling hyperlipidemia and obesity (Aznar and Sabater, 2020). In immunology, adamantane conjugates with amino acids and peptides exhibit **immunomodulatory properties**, modulating cytokine expression and T-cell responses (Stankiewicz et al., 2019). Additionally, adamantane has been employed as a scaffold for designing ligands targeting **G-protein coupled receptors (GPCRs)** and ion channels, broadening its scope in pharmacological research (Zhou et al., 2021). Collectively, these non-traditional applications demonstrate the adaptability of adamantane chemistry across diverse therapeutic domains.

4. Adamantane in Drug Delivery and Nanomedicine

Adamantane as a Building Block in Supramolecular Chemistry

The rigid, lipophilic, and sterically bulky cage of adamantane makes it a valuable **building block in supramolecular chemistry**. Its strong affinity for β-cyclodextrins, mediated by hydrophobic host–guest interactions, has been widely exploited in the design of drug delivery systems (Loftsson and Brewster, 2012). Adamantane-functionalized ligands serve as anchors for self-assembled nanostructures, enabling modular assembly of supramolecular complexes with controlled architectures (Aznar and Sabater, 2020). These interactions also provide reversible binding, which is useful in stimuli-responsive drug release systems (Fetih et al., 2017).

Dendrimer, Polymer, and Liposomal Formulations

Adamantane has been incorporated into **dendrimers** and **polymeric nanocarriers**, enhancing both drug loading capacity and targeting ability. Poly(amidoamine) (PAMAM) dendrimers functionalized with adamantane groups have demonstrated efficient encapsulation of hydrophobic drugs and nucleic acids, enabling delivery across biological barriers (Tomalia et al., 2016). Similarly, adamantane-modified polymers improve structural rigidity and lipophilicity, thereby enhancing cell membrane penetration (Liu et al., 2017). In **liposomal formulations**, adamantane conjugation increases membrane stability, prolongs circulation time, and improves drug retention (Kumar et al., 2022). Such versatility positions adamantane derivatives as multifunctional components in nanocarrier design.

Role in Improving Solubility, Stability, and Bioavailability

Poor solubility and bioavailability are major challenges in drug development. Adamantane moieties improve **aqueous solubility, chemical stability, and pharmacokinetics** of therapeutic agents by increasing hydrophobic interactions with carrier molecules (Loftsson and Brewster, 2012). For instance, adamantane-modified cyclodextrins have been used to solubilize hydrophobic drugs such as itraconazole and curcumin, significantly improving oral bioavailability (Chaudhuri and Ahmed, 2019). Furthermore, adamantane-based drug conjugates exhibit resistance to metabolic degradation, thereby enhancing half-life and reducing dosing frequency (Stankiewicz et al., 2019). These properties highlight adamantane's role in overcoming key formulation barriers.

Emerging Role in Targeted Delivery Systems and Theranostics

Recent advances demonstrate adamantane's role in **targeted delivery and theranostic applications**. Adamantane-functionalized nanoparticles can be conjugated with antibodies, peptides, or aptamers for active targeting of tumors and inflamed tissues (Wang et al., 2023). Additionally, adamantane-based supramolecular linkers enable the development of multifunctional nanoplatforms that integrate therapeutic and diagnostic modalities—commonly referred to as **theranostics** (Zhou et al., 2021). For example, adamantane-modified magnetic nanoparticles allow simultaneous drug delivery and imaging, offering precision in cancer therapy (Mandal et al., 2019). Such dual-functionality systems represent a frontier in nanomedicine, where adamantane serves as a **bridge between chemistry, biology, and clinical translation**.

5. Clinical Developments and Marketed Drugs

Status of FDA/EMA-Approved Adamantane-Based Drugs

The therapeutic success of adamantane derivatives is highlighted by several **FDA and EMA-approved drugs**, including **amantadine**, **rimantadine**, and **memantine**. Amantadine was first approved in the 1960s for influenza A prophylaxis and later for Parkinson's disease management due to its dopaminergic effects (Davies et al., 1964; Schapira and Olanow, 2004). Rimantadine, a second-generation analog, showed improved antiviral potency but eventually fell out of favor because of widespread resistance (Hay et al., 1985; Bright et al., 2006). Memantine, approved by both FDA and EMA in 2003, remains a frontline therapy for **moderate-to-severe Alzheimer's disease**, where it acts as a low-affinity NMDA receptor antagonist with neuroprotective benefits (Lipton, 2004; Parsons et al., 2007). Collectively, these approvals underscore adamantane's enduring clinical value despite challenges posed by drug resistance and changing therapeutic priorities.

Recent Clinical Trials: Design, Outcomes, Limitations

Recent clinical investigations have explored **novel applications of adamantane derivatives** beyond their historical uses. Trials involving memantine combinations with cholinesterase inhibitors reported additive cognitive benefits in Alzheimer's patients (Grossberg et al., 2013). Amantadine continues to be studied for **traumatic brain injury and fatigue in multiple sclerosis**, showing moderate efficacy but variable patient responses (Sawyer et al., 2016). During the COVID-19 pandemic, small clinical studies investigated amantadine's potential antiviral and immunomodulatory effects; while some reported symptomatic improvements, results remain inconclusive and limited by small sample sizes (Cortés-Borra et al., 2021). Major limitations across trials include **heterogeneous patient populations, lack of standardized dosing regimens, and limited long-term safety data**, all of which highlight the need for larger, well-controlled studies (Kumar et al., 2020).

Safety, Toxicity, and Pharmacokinetic Considerations

The **safety profile of adamantane derivatives** varies depending on their pharmacological target. Amantadine and rimantadine are generally well-tolerated at therapeutic doses but may induce **gastrointestinal upset, insomnia, and neuropsychiatric side effects** such as hallucinations and agitation, particularly in elderly patients (Hay et al., 1985; Stankiewicz et al., 2019). Memantine, in contrast, demonstrates a favorable safety profile with lower neuropsychiatric burden, though dizziness and headache are occasionally reported (Lipton, 2004; Matsunaga et al., 2015). Pharmacokinetic studies show that adamantane derivatives are well-absorbed orally, exhibit high lipophilicity, and are excreted largely unchanged in urine, which necessitates dose adjustments in renal impairment (Parsons et al., 2007). Resistance in viral applications further complicates efficacy, necessitating continuous structural optimization (Bright et al., 2006).

Market Trends and Global Therapeutic Demand

Market dynamics for adamantane-based drugs reflect **shifts in therapeutic demand**. The global sales of memantine remain strong due to the rising prevalence of Alzheimer's disease worldwide, with generics expanding accessibility in both developed and emerging markets (Zhou et al., 2021). Amantadine's clinical demand has shifted from influenza prophylaxis to neurological applications, particularly in Parkinson's disease and multiple sclerosis, ensuring continued but niche market presence (Schapira and Olanow, 2004). Rimantadine, once widely used, has largely disappeared from global antiviral markets due to resistance issues (Bright et al., 2006). Importantly, the COVID-19 pandemic revived interest in adamantane derivatives, stimulating new research funding and highlighting their potential in repurposing strategies (Wu et al., 2021). Looking forward, the market trajectory of adamantane-based therapies will likely depend on **emerging neurodegenerative disease therapies, combination regimens, and advances in drug delivery systems** that maximize efficacy while minimizing side effects.

6. Challenges and Limitations

Drug Resistance and Reduced Efficacy (Especially Antiviral)

One of the most significant challenges associated with adamantane derivatives lies in the **rapid emergence of viral resistance**. Mutations in the influenza A M2 proton channel, the primary target of amantadine and rimantadine, rendered these drugs largely ineffective after decades of clinical use (Bright et al., 2006). By 2009, global surveillance data indicated that over 90% of circulating influenza strains were resistant to adamantane-based antivirals, effectively eliminating them from frontline therapy (Nelson et al., 2009). Similar resistance concerns have been observed in other viral models, where structural mutations reduce binding affinity of adamantane derivatives to viral proteins (Kumar et al., 2020). This resistance crisis highlights the urgent need for **structural modifications, hybrid drug design, and combination regimens** to restore therapeutic value.

Poor Water Solubility and Metabolic Instability in Certain Derivatives

While the lipophilic cage of adamantane facilitates **membrane permeability**, it also contributes to **poor aqueous solubility and formulation challenges** (Liu et al., 2017). Many adamantane conjugates suffer from limited dissolution rates, reducing oral bioavailability and therapeutic effectiveness (Chaudhuri and Ahmed, 2019). Additionally, some derivatives undergo **rapid metabolic clearance or enzymatic instability**, resulting in suboptimal pharmacokinetics (Stankiewicz et al., 2019). Although formulation strategies such as cyclodextrin inclusion complexes and nanoparticle conjugates have been developed to address these issues, scalability and cost remain barriers to widespread clinical adoption (Fetih et al., 2017).

Safety and Tolerability Concerns in Long-Term Use

Adamantane derivatives exhibit a generally favorable short-term safety profile; however, **long-term administration raises tolerability concerns**. Amantadine, for instance, has been linked to neuropsychiatric side effects including confusion, insomnia, and hallucinations, particularly in elderly populations (Hay et al., 1985; Schapira and Olanow, 2004). Rimantadine showed slightly improved tolerability but still induced gastrointestinal and neurological adverse effects in some patients (Bright et al., 2006). While memantine has a better safety profile, reports of dizziness, headache, and rare renal complications highlight the need for **patient monitoring during chronic therapy** (Lipton, 2004; Matsunaga et al., 2015). These limitations underscore the importance of balancing potency with tolerability in future drug design.

Regulatory Hurdles and Intellectual Property Issues

The clinical development of adamantane-based therapeutics also faces **regulatory and patent-related challenges**. Regulatory agencies such as the FDA and EMA impose strict requirements for demonstrating safety and efficacy, which can be difficult for repurposed or structurally modified adamantane derivatives given the **resistance history** and **side-effect profiles** (Parsons et al., 2007). Moreover, many first-generation derivatives have expired patents, creating opportunities for generic production but limiting incentives for large-scale pharmaceutical investment in structural analogs (Zhou et al., 2021). Intellectual property disputes over hybrid molecules and delivery systems also complicate commercialization pathways (Wang et al., 2023). These barriers slow down translation from bench to bedside, despite promising preclinical findings.

7. Future Research Directions

Structure-Guided and AI-Driven Drug Design

The integration of **computational tools** with traditional medicinal chemistry is expected to accelerate the discovery of novel adamantane derivatives. Advances in **crystal structure analysis and molecular docking** enable rational design of molecules tailored to fit specific protein targets, such as viral proteases and ion channels (Zhou et al., 2021). At the same time, **AI-driven platforms** employing machine learning and deep generative models can predict drug–target interactions, optimize ADMET properties, and design virtual libraries of adamantane analogs with higher success rates (Wang et al., 2023). Combining **structure-guided design with AI algorithms** is likely to minimize trial-and-error approaches and reduce development timelines.

Multi-Target Drug Development (Polypharmacology)

The complex pathophysiology of modern diseases such as cancer, Alzheimer’s, and viral infections calls for **polypharmacological strategies**. Adamantane scaffolds, due to their unique three-dimensional rigidity and hydrophobicity, are well-suited for designing molecules that act on **multiple biological targets simultaneously** (Mandal et al., 2019). For instance, adamantane derivatives combining NMDA antagonism with anti-inflammatory properties have shown promise in neurodegeneration (Matsunaga et al., 2015). Similarly, antiviral-adamantane hybrids targeting both viral entry and replication pathways could reduce the likelihood of resistance (Kumar et al., 2020). This **multi-target approach** could provide more durable therapeutic outcomes in complex diseases.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 3206-3214 | ISSN:2251-6727

Adamantane Conjugates in Personalized Medicine

The rise of **personalized and precision medicine** has created opportunities for adamantane conjugates tailored to individual patient needs. Adamantane-based drug conjugates with **antibodies, peptides, or small interfering RNAs (siRNAs)** can be designed for targeted delivery, ensuring patient-specific therapeutic effects (Fetih et al., 2017). Moreover, **pharmacogenomics-guided therapy** may identify patient subgroups most responsive to adamantane-based neuroprotectants or antivirals (Stankiewicz et al., 2019). Personalized nanocarrier systems using adamantane anchors are particularly promising for oncology, where selective delivery can reduce off-target toxicity while maximizing efficacy (Kumar et al., 2022).

Potential in Combination Therapy with Biologics and Nanodrugs

Combination therapy remains a central pillar of future drug development, and adamantane derivatives are prime candidates for integration with **biologics and nanomedicines**. Their lipophilic framework makes them compatible with liposomal, dendrimeric, and polymeric drug delivery systems, allowing for synergistic effects (Loftsson and Brewster, 2012). Co-delivery of adamantane conjugates with **monoclonal antibodies, checkpoint inhibitors, or RNA-based drugs** could enhance therapeutic outcomes in cancer and infectious diseases (Mandal et al., 2019). Adamantane-based theranostic platforms, which combine imaging with therapy, further expand their role in **next-generation combination regimens** (Zhou et al., 2021).

Green Chemistry and Sustainable Synthesis Approaches

As sustainability becomes a global priority, the future of adamantane drug development must embrace **green chemistry principles**. Conventional synthetic routes often rely on hazardous reagents and multi-step processes, raising concerns about scalability and environmental impact (Chen et al., 2019). Recent progress in **solvent-free synthesis, biocatalysis, and recyclable catalysts** provides more sustainable methods for functionalizing adamantane derivatives (Li et al., 2020). Moreover, microwave-assisted and photocatalytic strategies have demonstrated higher yields with reduced energy consumption (Kamal et al., 2021). Implementing these eco-friendly methods can make adamantane-based drug discovery more cost-effective and environmentally responsible.

8. Conclusion

Adamantane derivatives have demonstrated remarkable adaptability as **versatile molecular scaffolds**, with applications spanning virology, neurology, oncology, antimicrobial therapy, and beyond. From their historical success as influenza antivirals and NMDA receptor antagonists to their emerging roles in nanomedicine and targeted therapies, adamantane-based compounds continue to influence the landscape of drug discovery in the 21st century. Their rigid diamondoid structure, lipophilicity, and capacity for functionalization provide a strong foundation for medicinal chemists seeking to design molecules with enhanced pharmacokinetic and pharmacodynamic profiles.

The contribution of adamantane chemistry to **modern drug discovery pipelines** is underscored by ongoing clinical evaluations, novel hybrid molecules, and computational design strategies that expand their therapeutic reach. Despite challenges such as drug resistance, solubility limitations, and regulatory barriers, innovations in structure-guided synthesis, AI-driven modeling, and nanotechnology-enabled delivery systems are reshaping the potential of these compounds.

Looking forward, the advancement of adamantane-based therapeutics will require **interdisciplinary collaboration**, bringing together medicinal chemists, pharmacologists, computational scientists, and clinicians. By integrating synthetic innovations, pharmacological insights, and sustainable approaches, the therapeutic frontier of adamantane derivatives can be fully realized. Their story illustrates not only the resilience of a classic scaffold but also its capacity to evolve into a cornerstone of **next-generation precision medicine**.

References

1. Aznar, E., & Sabater, S. (2020). Adamantane derivatives in supramolecular and biomedical chemistry. *Chemistry – A European Journal*, 26(9), 2025–2039.
2. Bright, R. A., Shay, D. K., Shu, B., Cox, N. J., & Klimov, A. I. (2006). Adamantane resistance

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 3206-3214 | ISSN:2251-6727

among influenza A viruses. *Journal of the American Medical Association*, 295(8), 891–894.

3. Chaudhuri, S., & Ahmed, A. (2019). Functionalization of adamantane for drug design. *European Journal of Medicinal Chemistry*, 170, 125–145.
4. Chen, G., Li, J., & Yang, J. (2019). Advances in C–H activation of adamantane derivatives. *Organic Letters*, 21(15), 6228–6233.
5. Cortés-Borra, C., López, A., & Ramírez, A. (2021). Repurposing amantadine in COVID-19: A clinical perspective. *Frontiers in Pharmacology*, 12, 654–663.
6. Davies, W. L., Grunert, R. R., Haff, R. F., McGahen, J. W., Neumayer, E. M., Paulshock, M., Watts, J. C., Wood, T. R., Hermann, E. C., & Hoffman, C. E. (1964). Antiviral activity of 1-adamantaneamine (amantadine). *Science*, 144, 862–863.
7. Fetih, G., Habib, F., & El-Sherbiny, I. (2017). Adamantane-modified carriers in drug delivery. *International Journal of Pharmaceutics*, 529(1–2), 134–147.
8. Gomha, S. M., Riyadh, S. M., & Mabkhot, Y. N. (2020). Adamantane-based heterocycles as potent antimalarial agents. *Bioorganic & Medicinal Chemistry*, 28(6), 115–125.
9. Grossberg, G. T., Manes, F., Allegri, R., Gutiérrez-Robledo, L. M., & Gloger, S. (2013). The efficacy of memantine combined with donepezil in Alzheimer's disease. *CNS Drugs*, 27(5), 405–414.
10. Haviernik, J., et al. (2018). Adamantane derivatives inhibit Zika virus replication. *Antiviral Research*, 160, 77–85.
11. Hay, A. J., Wolstenholme, A. J., Skehel, J. J., & Smith, M. H. (1985). The molecular basis of the specific anti-influenza action of amantadine. *EMBO Journal*, 4(11), 3021–3024.
12. Kamal, A., et al. (2021). Sustainable synthesis of adamantane derivatives using green chemistry approaches. *Green Chemistry*, 23, 514–529.
13. Kumar, R., Mehta, P., & Sharma, A. (2019). Adamantane-based prodrugs in anticancer therapy. *Journal of Medicinal Chemistry*, 62(18), 8320–8336.
14. Kumar, V., Rana, A., & Singh, R. (2020). Overcoming resistance in adamantane-based antivirals: Recent strategies. *Current Medicinal Chemistry*, 27(34), 5704–5720.
15. Kumar, S., et al. (2022). Adamantane-modified liposomes for CNS drug delivery. *Journal of Controlled Release*, 342, 33–45.
16. Li, Y., et al. (2020). Photocatalytic functionalization of adamantane: Towards sustainable drug synthesis. *Chemical Communications*, 56, 154–161.
17. Lipton, S. A. (2004). Paradigm shift in neuroprotection by NMDA receptor antagonists: Memantine and beyond. *Nature Reviews Drug Discovery*, 3(3), 210–219.
18. Loftsson, T., & Brewster, M. E. (2012). Cyclodextrins and adamantane derivatives in drug solubilization. *Journal of Pharmaceutical Sciences*, 101(9), 3019–3032.
19. Liu, X., et al. (2017). Adamantane functionalization strategies and biological applications. *Bioorganic & Medicinal Chemistry*, 25(24), 6799–6815.
20. Mandal, S., et al. (2019). Adamantane hybrids as multitarget therapeutic agents. *European Journal of Medicinal Chemistry*, 182, 111–121.
21. Matsunaga, S., Kishi, T., & Iwata, N. (2015). Memantine's role in Alzheimer's disease: Evidence from meta-analysis. *Alzheimer's Research & Therapy*, 7(1), 57–66.
22. Mehta, P., Singh, R., & Kumar, V. (2020). Adamantane-triazole hybrids as anticancer candidates. *Medicinal Chemistry Research*, 29, 211–225.
23. Mehta, N., et al. (2021). Repurposing adamantane scaffolds in COVID-19 drug discovery. *Drug Development Research*, 82, 1092–1101.

24. Nelson, M. I., et al. (2009). Global patterns of adamantane resistance in influenza viruses. *Journal of Infectious Diseases*, 199(1), 25–35.

25. Parsons, C. G., Danysz, W., & Quack, G. (2007). Memantine and the NMDA receptor: Mechanism and clinical implications. *International Journal of Geriatric Psychiatry*, 22(2), 103–113.

26. Prelog, V., & Seiwerth, R. (1933). Synthesis of adamantane. *Berichte der Deutschen Chemischen Gesellschaft*, 66, 178–183.

27. Rana, A., Sharma, R., & Kumar, V. (2022). Nanoparticle-assisted synthesis of adamantane derivatives. *Materials Today Chemistry*, 23, 100–112.

28. Sawyer, E., Mauro, L. S., & Ohlinger, M. J. (2016). Amantadine for traumatic brain injury and multiple sclerosis fatigue. *Annals of Pharmacotherapy*, 50(9), 725–733.

29. Schapira, A. H., & Olanow, C. W. (2004). Role of amantadine in Parkinson's disease therapy. *Movement Disorders*, 19(9), 967–975.

30. Sharma, A., Mehta, N., & Singh, R. (2020). Adamantane-derived kinase inhibitors in oncology. *Future Medicinal Chemistry*, 12(21), 1939–1953.

31. Stankiewicz, J., Piotrowska, D. G., & Nowak, K. (2019). Adamantane scaffolds in medicinal chemistry: Past, present and future. *Molecules*, 24(3), 498–513.

32. Tomalia, D. A., et al. (2016). Dendrimers in nanomedicine: Role of adamantane. *Accounts of Chemical Research*, 49, 336–349.

33. Von Itzstein, M. (2007). The story of adamantane and antiviral drug discovery. *Nature Reviews Drug Discovery*, 6(12), 967–974.

34. Wang, Q., Zhang, J., & Xu, L. (2023). Artificial intelligence in adamantane-based drug discovery. *Drug Discovery Today*, 28(3), 421–431.

35. Wu, C., et al. (2021). Adamantane derivatives as SARS-CoV-2 inhibitors. *Antiviral Research*, 188, 105–112.

36. Zhang, L., & Xu, Z. (2022). Machine learning in adamantane drug design. *Journal of Chemical Information and Modeling*, 62, 483–495.

37. Zhang, J., Wang, X., & Zhao, Y. (2018). Transition-metal catalyzed C–H activation of adamantane. *Catalysis Science & Technology*, 8(12), 3234–3241.

38. Zhou, Y., et al. (2021). Theranostic nanomedicine with adamantane conjugates. *Advanced Drug Delivery Reviews*, 173, 236–252.